In 2018, 165,000 men will be diagnosed with prostate cancer. The Prolaris test analyzes a patient's genetic profile to determine the best course of treatment.
Genetic testing helps over treatment. Approximately 90 percent of all localized prostate cancer patients receive surgery, radiation,or drug therapy. This occurs despite the high risk of treatment-related complications and the fact that the vast majority of prostate cancers do not cause death. There is widespread concern that the early detection of prostate cancer through screening programs alone has led to the over treatment of this localized disease.
Learn more here.